GlassScriptPhysician profile
George Alan Brant
NPI 1548526924
$2,785.49
in general payments reported to CMS, 2019-2025
22 companies · $942 in 2025
The $942 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $84.38 · 2020: $15.04 · 2021: $62.75 · 2022: $450 · 2023: $535 · 2024: $696 · 2025: $942.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,139 · Education: $33.82.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,139.44 |
| Education | $33.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $685.46 | 2022-2025 | Skyrizi, Rinvoq, Humira |
| Janssen Biotech, INC. | $334.26 | 2021-2025 | Tremfya |
| Lilly USA, LLC | $275.28 | 2021-2025 | Taltz, Ebglyss |
| Novartis Pharmaceuticals Corporation | $274.54 | 2019-2025 | |
| Galderma Laboratories, L.P. | $222.96 | 2022-2025 | Nemluvio |
| Biofrontera INC. | $203.30 | 2023-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Genzyme Corporation | $180.69 | 2021-2025 | |
| Ucb, INC. | $179.05 | 2024-2025 | Bimzelx |
| Sun Pharmaceutical Industries INC. | $52.10 | 2020-2025 | Ilumya |
| Mayne Pharma Commercial LLC | $47.39 | 2022-2025 | |
| Journey Medical Corporation | $45.66 | 2022-2023 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $42.12 | 2023 | Targretin |
| Organon LLC | $34.69 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $27.00 | 2022 | |
| Incyte Corporation | $25.74 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lnhc, INC | $25.01 | 2025 | Zelsuvmi |
| Encore Dermatology INC. | $23.13 | 2019 | |
| Amgen INC. | $22.97 | 2024 | Otezla |
| Leo Pharma INC. | $22.45 | 2025 | Anzupgo |
| Pfizer INC. | $22.25 | 2022 | |
| Almirall LLC | $19.85 | 2019 | |
| Verrica Pharmaceuticals INC. | $19.59 | 2025 | Ycanth |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Brant listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.